ABL1 and gastrointestinal stromal tumor: Notably, three out of four patients treated with BCR-ABL inhibitors in our study had solid tumors (gastrointestinal stromal tumors) and low immunogenicity among patients treated with BCR-ABL inhibitors is not attributed to hematologic malignancy.